|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Friedrich MG, Weisenberger DJ, Cheng JC,
et al: Detection of methylated apoptosis-associated genes in urine
sediments of bladder cancer patients. Clin Cancer Res.
10:7457–7465. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yakasai A, Allam M and Thompson AJ:
Incidence of bladder cancer in a one-stop clinic. Ann Afr Med.
10:112–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vlahou A: Back to the future in bladder
cancer research. Expert Rev Proteomics. 8:295–297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shan G and Xia Y: Expression and clinical
significance of RECK and MT1-MMP in bladder urothelium carcinoma
tissues. Chin J Cancer Prev Treat. 19:1722–1725. 2012.
|
|
6
|
Shan G, Shan S, Zhang X and Liu XH:
Expression and clinical sigificance of cyclin G1 and cyclin G2 in
transitional cell carcinoma of bladder. Chinese J Histochem
Cytochem. 18:268–273. 2009.
|
|
7
|
Shan G and Tang T: Expression and clinical
sigificance of ADO in transitional cell carcinoma of bladder.
Chinese J Histochem Cytochem. 20:267–271. 2011.
|
|
8
|
Shan G and Tang T: Expression and clinical
sigificance of tumor suppressor genes DPC4 and TGF-β1 in
transitional cell carcinoma of bladder. Chinese J Histochem
Cytochem. 20:491–495. 2011.
|
|
9
|
Shan G and Tang T: Expression and clinical
sigificance of CD82/KAI1 in transitional cell carcinoma of bladder.
Chinese J Histochem Cytochem. 22:185–188. 2013.
|
|
10
|
Shan G and Tang T: Expression and clinical
significance of PSCA and mesothelin in transitional cell carcinoma
of bladder. Chinese J Histochem Cytochem. 6:684–692. 2010.
|
|
11
|
Otieno S, Grace CR and Kriwacki RW: The
role of the LH subdomain in the function of the Cip/Kip
cyclin-dependent kinase regulators. Biophys J. 100:2486–2494. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jirawatnotai S, Hu Y, Michowski W, et al:
A function for cyclin D1 in DNA repair uncovered by protein
interactome analyses in human cancers. Nature. 474:230–234. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Makiyama K, Masuda M, Takano Y, et al:
Cyclin E overexpression in transitional cell carcinoma of the
bladder. Cancer Lett. 151:193–198. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Farley J, Smith LM, Darcy KM, et al
Gynecologic Oncology Group: Cyclin E expression is a signifieant
predictor of survival in advanced, suboptimally debulked ovarian
epithelial cancers: a Gynecologic Oncology Group study. Cancer Res.
63:1235–1241. 2003.PubMed/NCBI
|
|
15
|
Scuderi R, Palucka KA, Pokorvskaja K, et
al: Cyclin E overexpression in relapsed adult acute lymphoblastic
leukemias of B-cell lineage. Blood. 87:3360–3367. 1996.PubMed/NCBI
|
|
16
|
Eble JN, Sauter G, Epstein JI and
Sesterhenn IA: World Health Organization Classification of
TumorsPathology and Genetics of Tumors of the Urinary System and
Male Genital Organs. IARC Press; Lyon: 2004
|
|
17
|
Sobin LH, Gospodarowicz M and Wittekind C:
Urological tumoursTNM Classification of Malignant Tumors UICC
International Union Against Cancer. 7th. Wiley-Blackwell; pp.
262–265. 2009
|
|
18
|
Chen H, Xue J, Zhang Y, Zhu X, Gao J and
Yu B: Comparison of quantum dots immunofluorescence histochemistry
and conventional immunohistochemistry for the detection of
caveolin-1 and PCNA in the lung cancer tissue microarray. J Mol
Hist. 40:261–268. 2009. View Article : Google Scholar
|
|
19
|
Tang T and Zhang DL: Study on
extracellular matrix metalloproteinase inducer and human epidermal
growth factor receptor-2 protein expression in papillary thyroid
carcinoma using a quantum dot-based immunofluorescence technique.
Exp Ther Med. 9:1331–1335. 2015.PubMed/NCBI
|
|
20
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dhawan D, Ramos-Vara JA, Naughton JF, et
al: Targeting folate receptors to treat invasive urinary bladder
cancer. Cancer Res. 73:875–884. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sylvester RJ, van der Meijden AP,
Oosterlinck W, et al: Predicting recurrence and progression in
individual patients with stage Ta T1 bladder cancer using EORTC
risk tables: A combined analysis of 2596 patients from seven EORTC
trials. Eur Urol. 49:466–475; discussion. 475–477. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Amit D, Tamir S, Birman T, et al:
Development of targeted therapy for bladder cancer mediated by a
double promoter plasmid expressing diphtheria toxin under the
control of IGF2-P3 and IGF2-P4 regulatory sequences. Int J Clin Exp
Med. 4:91–102. 2011.PubMed/NCBI
|
|
25
|
Das SN, Khare P, Singh MK and Sharma SC:
Correlation of cyclin D1 expression with aggressive DNA pattern in
patients with tobacco-related intraoral squamous cell carcinoma.
Indian J Med Res. 133:381–386. 2011.PubMed/NCBI
|
|
26
|
Remacle F and Levine RD: Quantum dots as
chemical building blocks: elementary theoretical considerations.
Chemphyschem. 2:20–36. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu WW, Chang E, Drezek R and Colvin VL:
Water-soluble quantum dots for biomedical applications. Biochem
Biophys Res Commun. 348:781–786. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Koole R, Mulder WJ, van Schooneveld MM,
Strijkers GJ, Meijerink A and Nicolay K: Magnetic quantum dots for
multimodal imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol.
1:475–491. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li J, Huang X, Xie X, Wang J and Duan M:
Human telomerase reverse transcriptase regulates cyclin D1 and
G1/S phase transition in laryngeal squamous carcinoma.
Acta Otolaryngol. 131:546–551. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hwang CF, Cho CL, Huang CC, et al: Loss of
cyclin D1 and p16 expression correlates with local recurrence in
nasopharyngeal carcinoma following radiotherapy. Ann Oncol.
13:1246–1251. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Umekita Y, Ohi Y, Sagara Y and Yoshida H:
Over expression of cyclin D1 predicts for poor prognosis in
estrogen receptor-negative breast cancer patients. Int J Cancer.
98:415–418. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stamatakos M, Palla V, Karaiskos I, et al:
Cell cyclins: triggering elements of cancer or not? World J Surg
Oncol. 8:1112010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Freemantle SJ and Dmitrovsky E: Cyclin E
transgenic mice: discovery tools for lung cancer biology, therapy
and prevention. Cancer Prev Res (Phila). 3:1513–1518. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Musat M, Morris DG, Korbonits M and
Grossman AB: Cyclins and their related proteins in pituitary
tumourigenesis. Mol Cell Endocrinol. 326:25–29. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jung YJ, Lee KH, Choi DW, et al:
Reciprocal expressions of cyclin E and cyclin D1 in hepatocellular
carcinoma. Cancer Lett. 168:57–63. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pajalunga D and Crescenzi M: Regulation of
cyclin E protein levels through E2F-mediated inhibition of
degradation. Cell Cycle. 3:1572–1578. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Richter J, Wagner U, Kononen J, et al:
High-throughput tissue microarray analysis of cyclin E gene
amplification and overexpression in urinary bladder cancer. Am J
Pathol. 157:787–794. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li JQ, Miki H, Ohmori M, et al: Expression
of cyclin E and cyclin-dependent kinase 2 correlates with
metastasis and prognosis in colorectal carcinoma. Hum Pathol.
32:945–953. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Donnellan R, Kleinschmidt I and Chetty R:
Cyclin E immunoexpression in breast ductal cancinoma: pathologic
correlations and prognostic implications. Hum Pathol. 32:89–94.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhu HX: Cyclin E and tumor. Chinese
Medical Journal of Zhong Guo Yejin Gongye Yixue Zazhi. 20:86–88.
2003.(In Chinese).
|
|
41
|
Bales ES, Dietrich C, Bandyopadhyay D, et
al: High levels of expression of p27KIPl and cyclin E in invasive
primary malignant melanomas. J Invest Dermatol. 113:1039–1046.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Harwell RM, Porter DC, Danes C and
Keyomarsi K: Processing of cyclin E differs between normal and
tumor breast cells. Cancer Res. 60:481–489. 2000.PubMed/NCBI
|
|
43
|
Siu KT, Rosner MR and Minella AC: An
integrated view of cyclin E function and regulation. Cell Cycle.
11:57–64. 2012. View Article : Google Scholar : PubMed/NCBI
|
